Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 15 | 2004 | 38 | 0.630 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2003 | 4 | 0.230 |
Why?
|
| Bone Marrow | 10 | 2001 | 78 | 0.210 |
Why?
|
| Apoptosis | 8 | 1999 | 258 | 0.190 |
Why?
|
| Thrombosis | 1 | 2021 | 59 | 0.190 |
Why?
|
| Thalidomide | 3 | 2004 | 7 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 221 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2001 | 45 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2004 | 250 | 0.120 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1998 | 4 | 0.120 |
Why?
|
| Tretinoin | 2 | 1998 | 15 | 0.120 |
Why?
|
| Interphase | 4 | 1990 | 5 | 0.120 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 64 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 42 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 59 | 0.090 |
Why?
|
| Cytokines | 4 | 2001 | 349 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 4 | 1999 | 15 | 0.090 |
Why?
|
| Humans | 26 | 2021 | 29883 | 0.080 |
Why?
|
| Biomarkers | 2 | 2011 | 703 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2000 | 329 | 0.080 |
Why?
|
| Male | 13 | 2011 | 15870 | 0.070 |
Why?
|
| Cell Cycle | 3 | 1997 | 38 | 0.070 |
Why?
|
| Bromodeoxyuridine | 3 | 1997 | 6 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 270 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 4 | 0.060 |
Why?
|
| Arsenicals | 1 | 2004 | 9 | 0.060 |
Why?
|
| Oxides | 1 | 2004 | 13 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 135 | 0.060 |
Why?
|
| Female | 11 | 2011 | 16472 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 77 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2011 | 403 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2004 | 166 | 0.060 |
Why?
|
| Aged | 11 | 2011 | 9620 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2011 | 696 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 263 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 3 | 2001 | 124 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 494 | 0.050 |
Why?
|
| Cytarabine | 3 | 2001 | 10 | 0.050 |
Why?
|
| Aged, 80 and over | 7 | 2011 | 4932 | 0.050 |
Why?
|
| Middle Aged | 10 | 2011 | 9959 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 57 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 65 | 0.050 |
Why?
|
| Adult | 6 | 2021 | 8774 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 1998 | 23 | 0.050 |
Why?
|
| Anemia | 1 | 2001 | 98 | 0.040 |
Why?
|
| Connective Tissue | 2 | 1996 | 26 | 0.040 |
Why?
|
| Cytogenetic Analysis | 3 | 2004 | 6 | 0.040 |
Why?
|
| Remission Induction | 3 | 2004 | 103 | 0.040 |
Why?
|
| Palliative Care | 1 | 2000 | 149 | 0.040 |
Why?
|
| Hematopoiesis | 4 | 2001 | 13 | 0.040 |
Why?
|
| Ecchymosis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Cell Division | 4 | 2001 | 113 | 0.040 |
Why?
|
| Idoxuridine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Cell Lineage | 3 | 2004 | 30 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1126 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 22 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 9 | 0.040 |
Why?
|
| Leukemia, Myeloid | 2 | 1995 | 6 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1996 | 30 | 0.040 |
Why?
|
| DNA | 3 | 1997 | 123 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2004 | 3558 | 0.030 |
Why?
|
| Macrophages | 3 | 2001 | 128 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 149 | 0.030 |
Why?
|
| Phenotype | 2 | 2011 | 363 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 2466 | 0.020 |
Why?
|
| Mitoxantrone | 2 | 2001 | 5 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 16 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 83 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 77 | 0.020 |
Why?
|
| Time Factors | 2 | 2001 | 1642 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 148 | 0.020 |
Why?
|
| Amifostine | 2 | 2000 | 3 | 0.020 |
Why?
|
| Monosomy | 1 | 1990 | 1 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 4 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 28 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 135 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 102 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2001 | 644 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 2001 | 16 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 235 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 10 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1988 | 1 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 45 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 26 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 60 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 446 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1988 | 148 | 0.020 |
Why?
|
| Disease Progression | 2 | 2004 | 812 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 868 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 685 | 0.020 |
Why?
|
| DNA Fragmentation | 2 | 1996 | 7 | 0.020 |
Why?
|
| DNA Replication | 2 | 1996 | 12 | 0.020 |
Why?
|
| S Phase | 2 | 1999 | 10 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1996 | 79 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1188 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 2 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2004 | 2 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 15 | 0.020 |
Why?
|
| Infliximab | 1 | 2004 | 16 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 3 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2004 | 10 | 0.020 |
Why?
|
| Spleen | 1 | 2004 | 54 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 154 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 247 | 0.010 |
Why?
|
| Acute Disease | 2 | 1995 | 225 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 165 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2001 | 7 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Lymphokines | 1 | 2001 | 13 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 8 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 22 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2001 | 17 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 37 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 13 | 0.010 |
Why?
|
| Endothelium | 1 | 2001 | 14 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 75 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 20 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 46 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 68 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2001 | 35 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 93 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 232 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 412 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 4 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2000 | 7 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 28 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 14 | 0.010 |
Why?
|
| Hypotension | 1 | 2000 | 27 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 48 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 13 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 16 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 854 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 878 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1996 | 9 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 10 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 15 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1996 | 14 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 30 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 10 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 399 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 42 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2001 | 1954 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 240 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 347 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 14 | 0.010 |
Why?
|
| Adolescent | 1 | 1999 | 2335 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1992 | 455 | 0.010 |
Why?
|
| Metaphase | 1 | 1990 | 2 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 11 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 53 | 0.010 |
Why?
|
| Regeneration | 1 | 1989 | 27 | 0.010 |
Why?
|